Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses

Affiliations

• ¹ Nuffield Department of Medicine, University of Oxford, Oxford, UK.
• ² Faculty of Pharmaceutical Sciences, The University of British Columbia, British Columbia, Canada.
• ³ Cardio-Oncology Research Unit, Cardiovascular Analytics Group, Hong Kong, China.
• ⁴ Department of Medical Oncology, St Bartholomew's Hospital, London, UK; Department of Medical Oncology, University College London Hospital, London, UK.
• ⁵ Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ⁶ Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.
• ⁷ Emergency Medicine Unit, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
• ⁸ School of Data Science, City University of Hong Kong, Hong Kong, China.
• ⁹ Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China; Kent and Medway Medical School, Canterbury, UK.